The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis
- Conditions
- Chronic hepatitis C with osteoporosis
- Registration Number
- JPRN-UMIN000007070
- Lead Sponsor
- Department of Hepatology, Osaka City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
The following patients were excluded 1. women of childbearing potential and pregnancy, lactating women 2. allergic to ribavirin or other nucleoside analoges 3. an uncontrollable heart trouble( myocardial infarction, heart failure, or arrhythmia) 4. hemoglobibopathy ( thalassemia, sickle cell disease) 5. severe renal disease or Ccr<50mL/min 6. severe depression or psychosomatic disorders 7. severe liver diseases 8. autoimmune hepatitis or HBV 9. drug allegy against interferon 10. allergic to vaccine or biological preperations 11. concomitant herbal medication of Sho-saiko-to 13. history of interstitial pneumonia 14. patients who take active vitamin D3 other than Eldecalcitol 15. other conditions considerd inappropriate by attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method